SCHEMBL14906950

SCHEMBL14906950

COc1c(Cl)cc(Cl)cc1/C=N/NC(=O)c1ccc(O)c(O)c1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 2/20 0.58
LMNA P02545 5/20 0.50
HTT P42858 4/20 0.48
NPC1 O15118 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
RAB9A P51151 1/20 0.48
KMT2A Q03164 5/20 0.48
MAPT P10636 5/20 0.48
MEN1 O00255 4/20 0.48
KDM4E B2RXH2 6/20 0.47
USP2 O75604 1/20 0.47
MCOLN3 Q8TDD5 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PTGES O14684 1/20 0.47
KDM1A O60341 2/20 0.47
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
NTRK1 P04629 1/20 0.46
GCGR P47871 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14907015 0.86 PIK3CG (0.72) PIK3CGLMNAHTTNPC1SMN1; SMN2
SCHEMBL14906947 0.83 GCGR (0.54) LMNAHTTNPC1SMN1; SMN2RAB9A
SCHEMBL14907116 0.83 KDM4E (0.60) PIK3CGLMNAHTTNPC1SMN1; SMN2
SCHEMBL14907016 0.83 MEN1 (0.53) PIK3CGLMNAHTTNPC1SMN1; SMN2
SCHEMBL14907018 0.81 PIK3CG (0.63) PIK3CGLMNAHTTNPC1SMN1; SMN2
SCHEMBL14906902 0.81 GCGR (0.62) HTTNPC1RAB9AKMT2AMAPT
SCHEMBL14907007 0.81 PIK3CG (0.58) PIK3CGLMNAHTTNPC1SMN1; SMN2
SCHEMBL14907019 0.81 PIK3CG (0.71) PIK3CGLMNAHTTNPC1SMN1; SMN2
SCHEMBL14906949 0.80 MAPT (0.51) PIK3CGLMNAHTTNPC1SMN1; SMN2
SCHEMBL14907035 0.80 GCGR (0.58) PIK3CGLMNAHTTNPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9873661-B2 Small molecule malarial Aldolase-TRAP enhancers and glideosome inhibitors NEW YORK UNIVERSITY (US) 2018-01-23 US disclosed
US-20140275088-A1 SMALL MOLECULE MALARIAL ALDOLASE-TRAP ENHANCERS AND GLIDEOSOME INHIBITORS THE JOHNS HOPKINS UNIVERSITY 2014-09-18 US disclosed
WO-2013063243-A1 SMALL MOLECULE MALARIAL ALDOLASE-TRAP ENHANCERS AND GLIDEOSOME INHIBITORS NEW YORK UNIVERSITY (US) 2013-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275088-A1 SMALL MOLECULE MALARIAL ALDOLASE-TRAP ENHANCERS AND GLIDEOSOME INHIBITORS ALDOA, DERA, TALDO1 PIK3CG 3964/4885LMNA 1944/4885HTT 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.